Your browser version is outdated. We recommend that you update your browser to the latest version.


Our technology is based on administration of liposomes loaded with a TLR7 agonist to boost the immune system as a novel approach to stimulate the immune system and educate the immune system to recognize and eliminate metastatic disease.

Our TLR7 agonist has demonstrated a strong antitumor activity in combination with radiotherapy and chemotherapy.


Key benefits of the MonTa Biosciences' technology are:

  • Demonstrated complete remission in syngenic mosde models
  • Lead candidate show no toxicity in optimal dosing regimen
  • Promising technology to complement existing therapies like radiation, chemotherapy, therapeutic antibodies and immune checkpoint inhibitors.